FBR Capital Resumes Regulus Therapeutics (RGLS) at Outperform

FBR Capital transfers and resumes coverage on Regulus Therapeutics (NASDAQ: RGLS) with an Outperform rating and a price target of $30.00.

Analyst Christopher James commented, "Regulus is a biotech company focused on the discovery and development of drugs that target and regulate microRNA to treat cancer and orphan diseases. The company's lead drug candidate, RG-101, is poised to enter Phase II development for hepatitis C (HCV), with multiple data readouts expected for 2015. We believe this drug will play a significant role in the HCV landscape. In addition, the company's second candidate, RG-012, recently received orphan drug status for Alport Syndrome (AS). Finally, the recent nomination of a third clinical candidate, RG-125, should create incremental value to the overall microRNA platform. Given the strength of the HCV data in particular and the recent acquisitions of HCV companies, we see the potential for a number of meaningful catalysts for the stock and believe RGLS shares are undervalued at current levels."

For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.

Shares of Regulus Therapeutics closed at $17.30 yesterday.

You May Also Be Interested In

• RBC Capital Starts Inspire Medical Systems (INSP) at Outperform
• Tractor Supply Company (TSCO) PT Raised to $275 at Telsey
• Jefferies Downgrades ULTA Salon (ULTA) to Hold, 'Competition Intensifying & Prestige Refresh Needed'